| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3340266 | Allergologia et Immunopathologia | 2007 | 7 Pages |
Abstract
Once-daily administration of 800 μg of inhaled budesonide administered by MDI plus spacer was more effective in controlling symptoms and improving BHR than fractionating the dose to 400 μg twice daily. The differences observed in this study could have been due to the greater adherence to treatment in patients in the once-daily group.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
J. Mallol, V. Aguirre,